title: HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies.
abstract: OBJECTIVE
  To evaluate deaths from AIDS-defining malignancies (ADM) and non-AIDS-defining malignancies (nADM) in the D:A:D Study and to investigate the relationship between these deaths and immunodeficiency.
  
  
  METHODS
  Observational cohort study.
  
  
  METHODS
  Patients (23 437) were followed prospectively for 104 921 person-years. We used Poisson regression models to identify factors independently associated with deaths from ADM and nADM. Analyses of factors associated with mortality due to nADM were repeated after excluding nADM known to be associated with a specific risk factor.
  
  
  RESULTS
  Three hundred five patients died due to a malignancy, 298 prior to the cutoff for this analysis (ADM: n = 110; nADM: n = 188). The mortality rate due to ADM decreased from 20.1/1000 person-years of follow-up [95% confidence interval (CI) 14.4, 25.9] when the most recent CD4 cell count was <50 cells/microl to 0.1 (0.03, 0.3)/1000 person-years of follow-up when the CD4 cell count was more than 500 cells/microl; the mortality rate from nADM decreased from 6.0 (95% CI 3.3, 10.1) to 0.6 (0.4, 0.8) per 1000 person-years of follow-up between these two CD4 cell count strata. In multivariable regression analyses, a two-fold higher latest CD4 cell count was associated with a halving of the risk of ADM mortality. Other predictors of an increased risk of ADM mortality were homosexual risk group, older age, a previous (non-malignancy) AIDS diagnosis and earlier calendar years. Predictors of an increased risk of nADM mortality included lower CD4 cell count, older age, current/ex-smoking status, longer cumulative exposure to combination antiretroviral therapy, active hepatitis B infection and earlier calendar year.
  
  
  CONCLUSIONS
  The severity of immunosuppression is predictive of death from both ADM and nADM in HIV-infected populations.
authors.affiliation: Dipartimento di Medicina, Chirurgia e Odontoiatria, Clinica di Malattie Infettive e Tropicali, Azienda Ospedaliera-Polo Universitario San Paolo, via A Di Rudinì 8- 20142 Milano, Italy. antonella.darminio@unimi.it
authors.forename: Antonella d'Arminio
authors.initials: Ad
authors.lastname: Monforte
authors.forename: Donald
authors.initials: D
authors.lastname: Abrams
authors.forename: Christian
authors.initials: C
authors.lastname: Pradier
authors.forename: Rainer
authors.initials: R
authors.lastname: Weber
authors.forename: Peter
authors.initials: P
authors.lastname: Reiss
authors.forename: Fabrice
authors.initials: F
authors.lastname: Bonnet
authors.forename: Ole
authors.initials: O
authors.lastname: Kirk
authors.forename: Matthew
authors.initials: M
authors.lastname: Law
authors.forename: Stephane
authors.initials: S
authors.lastname: De Wit
authors.forename: Nina
authors.initials: N
authors.lastname: Friis-Møller
authors.forename: Andrew N
authors.initials: AN
authors.lastname: Phillips
authors.forename: Caroline A
authors.initials: CA
authors.lastname: Sabin
authors.forename: Jens D
authors.initials: JD
authors.lastname: Lundgren
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D019380:Anti-HIV Agents / Q000008:administration & dosage; D018791:CD4 Lymphocyte Count; D004334:Drug Administration Schedule; D004812:Epidemiologic Methods; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000276:immunology / Q000401:mortality; D018451:Homosexuality, Male / Q000706:statistics & numerical data; D006801:Humans; D016867:Immunocompromised Host; D016483:Lymphoma, AIDS-Related / Q000276:immunology / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000276:immunology / Q000401:mortality / Q000821:virology*; D012737:Sex Factors; D055815:Young Adult
chemical_list: D019380:Anti-HIV Agents